Search Results

HOME > SEARCH > SEARCH RESULTS

Refine by Audience:

Your search for pilot research returned 285 results.

Selected filters: Physicians

Displaying 41 to 50 of 285 records
Sort by: Page: << Prev 2… 3… 4… 5… 6… 7… 8… Next >>

PET Imaging Validates Use of Common Cholesterol Drug to Enhance HER2-Targeted Cancer Therapy – Oct 12, 2023
A novel therapeutic approach combining HER2-targeted therapies with the cholesterol-lowering drug lovastatin can reduce the number of cancer treatments required to prevent tumor growth, according to research published in JNM.
Message from the President – Oct 10, 2023
SNMMI President Helen Nadel highlights recent achievements, global collaborations, advocacy efforts, and upcoming SNMMI meetings.
Molecular Imaging and Breast Cancer - 11/8/23, Seattle, WA – Oct 5, 2023
Dinner Symposium - Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments
FDA Approves Widely Used Imaging Agent for Respiratory Disease – Sep 29, 2023
The FDA has approved the imaging agent Technegas for use in ventilationperfusion studies to diagnose pulmonary embolism and other respiratory pathologies.
Novel Tau PET Tracer Exhibits High Sensitivity and Specificity, Allowing for Earlier Identification of Alzheimers Disease – Sep 28, 2023
A new tau PET radiotracer, F-18 SNFT-1, has been found to be more effective than existing tau PET radiotracers in identifying Alzheimers disease in its earliest stages, according to research published in JNM.
Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients – Sep 27, 2023
A new imaging agent, Ga-68-ABY-025, can predict early metabolic response to human epidermal growth factor receptor 2 (HER2)-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in JNM.
First Three Facilities Accredited in SNMMI/IAC Radiopharmaceutical Therapy Accreditation Program – Sep 25, 2023
SNMMI and the Intersocietal Accreditation Commission are pleased to announce the first three facilities to be awarded the new Radiopharmaceutical Therapy Accreditation.
Nuclear Medicine Treatment Cures Lethal Form of Ovarian Cancer in Preclinical Setting – Sep 18, 2023
A new 225Ac-DOTA-based pre-targeted radioimmunotherapy system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects, according to research published in JNM.
JNM Publishes Consensus Statement on Patient Selection and Appropriate Use of Lu-177 PSMA-617 Radionuclide Therapy – Sep 1, 2023
SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with Lu-177 PSMA radionuclide therapy.
Therapy COE 2023 Young Investigator Awards – Aug 30, 2023
Winners of the 2023 Young Investigator Awards for the Therapy Center of Excellence

Displaying 41 to 50 of 285 records
Page: << Prev 2… 3… 4… 5… 6… 7… 8… Next >>